Navigation Links
ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
Date:7/16/2014

FREDERICK, Md., July 16, 2014 /PRNewswire/ -- ImQuest Pharmaceuticals was recently notified by the US Food and Drug Administration of the approval of its Investigational New Drug (IND) application to study the safety in Phase 1 clinical trials of its vaginal gel containing the nonnucleoside reverse transcriptase HIV Inhibitor IQP-0528. Preclinical studies have shown that IQP-0528 is highly effective against virus strains found throughout the world, prevents HIV transmission in cultured cells, causes sterilization of cultures infected with HIV, and acts in concert with other approved HIV drugs to inhibit the virus. The IQP-0528 vaginal gel is being developed with the goal of preventing the sexual transmission of HIV to women throughout the world.

ImQuest plans to evaluate the safety of the IQP-0528 vaginal gel in a Phase I clinical trial at medical centers in the United States and expects to begin recruiting women for the trial by the end of the year. This marks the company's first product to receive FDA approval for clinical trials.

"The approval of our IND by the FDA is a major and highly significant milestone for ImQuest's Women's Health and Prevention programs focused on the protection of susceptible women from infection," said Dr. Robert Buckheit, Jr., President and Chief Scientific Officer of ImQuest. "In light of the unique properties of IQP-0528 we anticipate that the IQP-0528-containing gel will be a highly successful prevention agent and will be a first step towards our development of subsequent prevention and women's health products."

ImQuest Pharmaceuticals developed the HIV inhibitor in partnership with Samjin Pharmaceutical Co. Ltd of Seoul Korea. Preclinical testing was conducted by ImQuest BioSciences of Frederick, Maryland using the company's newly launched ImQuestSUCCESS™ platform, w
'/>"/>

SOURCE ImQuest BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
2. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
3. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
4. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
5. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
6. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
7. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
8. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
9. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
10. Avanir Pharmaceuticals to Participate in Two Conferences in December
11. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015   Hospira, Inc. ... biosimilars, today announced that its partner, Celltrion – a global ... the National Health Surveillance Agency in Brazil ... monoclonal antibody approved for use in Brazil ... Hospira also markets and sells biosimilar infliximab in 26 ...
(Date:6/2/2015)... GERMANTOWN, Md. , June 2, 2015 /PRNewswire/ ... a leader in synthetic biology, announced today the ... as Senior Vice President, Consumer Sector.  Mr. Jarry ... biologically-based solutions in products and applications for consumer ... Intrexon over 30 years of experience in leading ...
(Date:6/2/2015)... Mass. , June 2, 2015  Alere ... in rapid diagnostics, joined the White House Antibiotic ... of commitments to support and advance the President,s ... Company,s commitments include a number of measurable goals ... when achieved, will help healthcare providers protect their ...
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. ... the Moenninghoff product line . , ... announce that the R.M. Hoffman Company will be representing ... in 1916, this is a strategically important step. ... of professional distributor we need to successfully grow our ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3
... ... , ... Waterville, ME (Vocus) April 15, 2010 -- Cerealus Holdings, in collaboration with the ... Next Generation Strength + Retention System.” Originally patented by DuPont and later developed ...
... ... turning the corner on jobs, with the worst behind us. With only 308 job cuts announced ... a steady unemployment rate for two years running, they may just be correct. , ... (Vocus) April 15, 2010 -- If the absence of ...
... ... ... when paying taxes is on every American’s mind, Cole-Parmer makes the process painless—for online ... checking out—adding shipping costs and taxes—now takes mere seconds to complete. Customers simply type ...
Cached Biology Technology:Cerealus Announces Licensing Agreement for Bio-Based Ceregel™, A Next Generation Strength and Retention System 2The MedZilla Report for April 2010 - Pharma Layoffs Drop Below 400 in March; Health Care Adds Another 27,000 Jobs 2The MedZilla Report for April 2010 - Pharma Layoffs Drop Below 400 in March; Health Care Adds Another 27,000 Jobs 3Cole-Parmer Announces Automatic Tax Calculation for Online Purchases 2
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)...  Technology is rapidly advancing, outpacing enterprises, ability to ... Passwords and their management are soon to be rendered ... such as those developed by the FIDO Alliance™. With ... for BYOD, COPE, IoT, and mobile payments, the interconnected ... In response to the call for seamless, ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... SACRAMENTO, Calif. -- The University of California, Davis, and ... have signed a historic agreement that will change the ... states, and foster critical breakthroughs in the areas of ... new partnership will establish a state-of-the-art BGI sequencing facility ...
... In an experiment on rats, European researchers have proved ... cause to the stomach mucous membrane. Published in the ... to improving the treatment of stomach ulcers. A ... the protecting effect that strawberries have in a mammal ...
... era of environmental consciousness, many buildings are being outfitted to ... literally. Elizabeth Demaray, an associate professor of fine arts, ... skyscrapers to counteract the lack of native vegetation found in ... part of New York,s Art in Odd Places Festival from ...
Cached Biology News:UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 3Strawberries protect the stomach from alcohol 2Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... Terminal deoxynucleotidyl transferase (TdT) is an intracellular ... cortical thymocytes and minor subpopulation of bone ... and increased numbers of TdT cells are ... leukaemias and lymphomas. Presence of TdT thus ...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: